Naringenin ameliorates streptozotocin-induced diabetic rat renal impairment by downregulation of TGF-β1 and IL-1 via modulation of oxidative stress correlates with decreased apoptotic events

Pharmaceutical Biology

Volumn 54, Issue 9, 2016, Pages 1616-1627

  Roy, Souvik ^a   Ahmed, Faiqa ^a   Banerjee, Sritama ^a   Saha, Urmi ^a  

^a NSHM Business School   (India)

Author keywords

Catalase; diabetes; histopathology; immunohistochemistry; malondialdehyde; reduce glutathione; terminal dUTP nick end labeling

Indexed keywords

CATALASE; GLUTATHIONE; INTERLEUKIN 1; MALONALDEHYDE; NARINGENIN; SUPEROXIDE DISMUTASE; TRANSFORMING GROWTH FACTOR BETA1; ANTIDIABETIC AGENT; ANTIOXIDANT; BIOLOGICAL MARKER; FLAVANONE DERIVATIVE; GLUCOSE BLOOD LEVEL; STREPTOZOCIN; TGFB1 PROTEIN, RAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME ASSAY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; OXIDATIVE STRESS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; ANIMAL; APOPTOSIS; BLOOD; CHEMICALLY INDUCED; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DOSE RESPONSE; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; KIDNEY; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TIME FACTOR; WISTAR RAT;

ANIMALS; ANTIOXIDANTS; APOPTOSIS; BIOMARKERS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FLAVANONES; HYPOGLYCEMIC AGENTS; INTERLEUKIN-1; KIDNEY; MALE; OXIDATIVE STRESS; RATS, WISTAR; SIGNAL TRANSDUCTION; STREPTOZOCIN; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84981725417     PISSN: 13880209     EISSN: 17445116     Source Type: Journal    
DOI: 10.3109/13880209.2015.1110599     Document Type: Article

References (54)

1. E.M.Allister, N.M.Borradaile, J.Y.Edwards, M.W.Huff. 2005a. Inhibition of microsomal triglyceride transfer protein expression and apolipoprotein B100 secretion by the citrus flavonoid naringenin and by insulin involves activation of the mitogen-activated protein kinase pathway in hepatocytes. Diabetes 54:1676–1683.
2. E.M.Allister, N.M.Borradaile, J.Y.Edwards,. 2005b. Inhibition of microsomal triglyceride transfer protein expression and apolipoprotein B100 secretion by the Citrus flavonoid naringenin and by insulin involves activation of the mitogen-activated protein kinase pathway in hepatocytes. J Lipid Res. 49:2218–2229.
3. L.Al-Shamaony, S.M.Al-Khazaraji, I.A.Twaiji 1994. Hypoglycaemic effect of Artemisia herba alba. II. Effect of a valuable extract on some blood parameters in diabetic animals. J Ethnopharmacol. 43:167–171.
4. L.Andrade, J.M.Vieira, R.Safirstein 2000. How cells die counts. AM J Kidney Dis. 36:662–668.
5. O.E.Ayodele, C.O.Alebiosu, B.L.Salako 2004. Diabetic nephropathy – a review of the natural history, burden, risk factors and treatment. J Natl Med Assoc. 96:1445–1454.
6. J.W.Baynes 1991. Role of oxidative stress in development of complications in diabetes. Diabetes 40:405–412.
7. D.Bonnefont 2002. Glucose and reactive oxygen species. Curr Opin Clin Nutr Metab Care 5:561–568.
8. J.A.Buege, S.D.Aust 1984. Microsomal lipid peroxidation. Meth Enzymol. 105:302–310.
9. S.M.Cochrane, G.B.Robinson 1995. In vitro glycation of glomerular basement membrane alters its permeability:a possible mechanism in diabetic complications. FEBS Lett. 375:41–44.
10. E.M.Erin, J.M.Assini, B.G.Sutherland,. 2011. Naringenin decreases progression of atherosclerosis by improving dyslipidemia in high-fat-fed low-density lipoprotein receptor-null mice. Arterioscler Thromb Vasc Biol. 30:742–748.
11. J.L.Evans, I.D.Goldfine, B.A.Maddux,. 2002. Oxidative stress and stress activated signaling pathways:a unifying hypothesis of type 2 diabetes. Endocr Rev. 23:599–622.
12. J.M.Forbes, M.T.Coughlan, M.E.Cooper 2008. Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 57:1446–1454.
13. S.Goldfarb, F.N.Ziyadeh 2001. TGF-beta:a crucial component of the pathogenesis of diabetic nephropathy. Trans Am Clin Climatol Assoc. 112:27–33.
14. J.Goldwasser, P.Y.Cohen, W.Lin, D.Kitsberg,. 2011. Naringenin inhibits the assembly and long-term production of infectious hepatitis C virus particles through a PPAR-mediated mechanism. J Hepatol. 55:963–971.
15. J.Goldwasser, P.Y.Cohen, E.Yang,. 2010. Transcriptional regulation of human and rat hepatic lipid metabolism by the grapefruit flavonoid naringenin:role of PPARalpha, PPARgamma and LXRalpha. PLoS One 5:e12399.
16. M.G.L.Hertog, P.C.H.Hollman, B.Van De Putte 1993. Content of potentially anticarcinogenic flavonoids of tea infusions, wines and fruit juices. J Agric Food Chem. 41:1242–1246.
17. R.Jin, V.T.Chow, P.H.Tan,. 2002. Metallothionein 2A expression is associated with cell proliferation in breast cancer. Carcinogenesis 23:81–86.
18. L.H.Johansson, L.A.Hakan Borg 1988. A spectrophotometric method for determination of catalase activity in small tissue samples. Anal Biochem. 174:331–336.
19. D.S.Jung, S.H.Lee, S.H.Kwak,. 2012. Apoptosis occurs differentially according to glomerular size in diabetic kidney disease. Nephrol Dial Transplant. 27:259–266.
20. U.J.Jung, H.J.Kim, J.S.Lee,. 2003. Naringin supplementation lowers plasma lipids and enhances erythrocyte antioxidant enzyme activities in hypercholesterolemic subjects. Clin Nutr. 22:561–568.
21. J.F.Kerr, G.C.Gobe, C.M.Winterford,. 1995. Anatomical methods in cell death. Methods Cell Biol. 46:1–27.
22. S.Y.Kim, H.J.Kim, M.K.Lee,. 2006. Naringin time dependently lowers hepatic cholesterol biosynthesis and plasma cholesterol in rats fed high-fat and high-cholesterol diet. J Med Food. 9:582–586.
23. R.Klein 1995. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care 18:258–268.
24. E.Kurowska, N.Borradaile, J.D.Spence,. 2000. Hypocholesterolemic effects of dietary citrus juices in rabbits. Nutr Res. 20:121–129.
25. E.M.Kurowska, J.A.Manthey, A.Casaschi,. 2004. Modulation of HepG2 Cell net apolipoprotein B secretion by the Citrus polymethoxyflavone, tangeretin. Lipids 39:143–115.
26. P.Masiello, C.Broca, R.Gross,. 1998. Experimental NIDDM:development of a new model in adult rats administered streptozotocin and nicotinamide. Diabetes 47:224–229.
27. S.V.Mclennan, S.Hefernan, L.Wright 1991. Changes in hepatic glutathione metabolism in diabetes. Diabetes 40:344–348.
28. C.J.Mullarkey, D.Edelstein, L.Brownlee 1990. Free radical generation by early glycation products:a mechanism for accelerated atherogenesis in diabetes. Biochem Biophys Res Commun. 173:932–939.
29. S.Nagata 1997. Apoptosis by death factor. Cell 88:355–365.
30. J.F.Navarro, F.J.Milena, C.Mora,. 2006. Renal pro-inflammatory cytokine gene expression in diabetic nephropathy:effect of angiotensin-converting enzyme inhibition and pentoxifylline administration. Am J Nephrol. 26:562–570.
31. E.Nishio, Y.Watanabe 1997. Transforming growth factor beta is a modulator of platelet-derived growth factor action in vascular smooth muscle cells:a possible role for catalase activity and glutathione peroxidase activity. Biochem Biophys Res Commun. 232:1–4.
32. E.N.Obineche, E.Mensah-Brown, S.I.Chandranath,. 2001. Morphological changes in the rat kidney following long-term diabetes. Arch Physiol Biochem. 109:241–245.
33. D.E.Pagila, W.N.Valentine 1967. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med. 70:158–169.
34. P.Palsamy, S.Subramanian 2011. Resveratrol protects diabetic kidney by attenuating hyperglycemia-mediated oxidative stress and renal inflammatory cytokines via Nrf2-Keap1 signaling. Biochim Biophys Acta 1812:719–731.
35. N.L.Parinandi, E.W.Thompson, H.H.O.Schmid 1990. Diabetic heart and kidney exhibit increased resistance to lipid peroxidation. Biochim Biophys Acta. 1047:63–69.
36. A.Ramachandran, C.Snehalata 2009. Current scenario of diabetes in India. J Diabetes 1:18–28.
37. F.M.Rauscher, A.Ruth, J.B.Watkins 2001. Effects of isoeugenol on oxidative stress pathways in normal and streptozotocin induced diabetic rats. J Biochem Mol Toxicol. 15:159–164.
38. K.Ravi, B.Ramachandran, S.Subramanian 2004. Protective effect of Eugenia jambolana seed kernel on tissue antioxidants in streptozotocin-induced diabetic rats. Biol Pharm Bull. 27:1212–1217.
39. A.S.Reddi, J.S.Bollineni 1997. Renal cortical expression of mRNAs for antioxidant enzymes in normal and diabetic rats. Biochem Biophys Res Commun. 235:598–601.
40. A.S.Reddi, R.A.Davalos 1990. Diabetic nephropathy. An update. Arch Intern Med. 150:31–43.
41. G.Remuzzi, A.Schieppati, P.Ruggenenti 2002. Clinical practice. Nephropathy in patients with type 2 diabetes. N Engl J Med. 346:1145–1151.
42. J.Renugadevi, S.M.Prabu 2009. Naringenin protects against cadmium-induced oxidative renal dysfunction in rats. Toxicology 256:128–134.
43. S.Roy, N.Rahaman, F.Ahmed,. 2013. Naringenin attenuates testicular damage, germ cell death and oxidative stress in streptozotocin induced diabetic rats. J Appl Biomed. 11:195–208.
44. A.K.Salahudeen, V.Kanji, J.F.Reckelhoff, J.M.Schimdt. 1997. Pathogenesis of diabetic nephropathy:a radical approach. Nephrol Dial Transplant 12:664–668.
45. C.Sassy-Prigent, D.Heudes, S.Jouquey,. 2000. Early glomerular macrophage recruitment in streptozotocin-induced diabetic rats. Diabetes 49:466–475.
46. J.R.Schelling, R.P.Cleveland 1999. Involvement of Fas-dependent apoptosis in renal tubular epithelial cell deletion in chronic renal failure. Kidney Int. 56:1313–1316.
47. K.Sharma, Y.Jin, J.Guo,. 1996. Neutralization of TGF beta by anti TGF beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ induced diabetic mice. Diabetes 45:522–530.
48. M.Shulman, M.Cohen, A.Soto-Gutierrez,. 2011. Enhancement of naringenin bioavailability by complexation with hydroxypropoyl-β-cyclodextrin. PLoS One 6:e18033.
49. J.J.Strain 1991. Disturbances of micronutrient and antioxidant status in diabetes. Proc Nutr Soc. 50:591–604.
50. H.Sugiyama, N.Kashihara, H.Makino,. 1996. Apoptosis in glomerular sclerosis. Kidney Int. 49:103–111.
51. D.Wagener, J.H.Dekker, A.Berden,. 2009. The role of reactive oxygen species in apoptosis of the diabetic kidney. Diab Apop 14:1451–1458.
52. S.Wild, G.Roglic, A.Green,. 2004. Global prevalence of diabetes:estimates for the year 2000 and projections for 2030. Diabetes Care 27:1047–1053.
53. S.Yamagishi, T.Imaizumi 2005. Diabetic vascular complications:pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des. 11:2279–2299.
54. F.N.Ziyadeh, B.B.Hoffman, D.C.Han,. 2000. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci USA 97:8015–8020.